BACKGROUND: We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma. METHODS: A total of 64 patients with recurrent/progressive low-grade glioma were enrolled in this single-center study that stratified patients into astrocytoma and oligodendroglioma cohorts. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 400 mg per day for patients not on enzyme-inducing antiepileptic drugs (EIAEDs) and at 500 mg twice a day if on EIAEDs. The primary endpoint was progression-free survival at 12 months (PFS-12) and secondary endpoints were safety, median progression-free survival, and radiographic response rate. RESULTS: Thirty-two patients were enrolled into each cohort. Eleven patients (17%) had before radiotherapy and 24 (38%) had received before chemotherapy. The median PFS and PFS-12 were 11 months and 39%, respectively. Outcome did not differ between the histologic cohorts. No patient achieved a radiographic response. The most common grade 3 or greater adverse events were neutropenia (11%), thrombocytopenia (3%), and diarrhea (3%). CONCLUSIONS: Imatinib plus hydroxyurea was well tolerated among recurrent/progressive LGG patients but this regimen demonstrated negligible antitumor activity.
BACKGROUND: We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma. METHODS: A total of 64 patients with recurrent/progressive low-grade glioma were enrolled in this single-center study that stratified patients into astrocytoma and oligodendroglioma cohorts. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 400 mg per day for patients not on enzyme-inducing antiepileptic drugs (EIAEDs) and at 500 mg twice a day if on EIAEDs. The primary endpoint was progression-free survival at 12 months (PFS-12) and secondary endpoints were safety, median progression-free survival, and radiographic response rate. RESULTS: Thirty-two patients were enrolled into each cohort. Eleven patients (17%) had before radiotherapy and 24 (38%) had received before chemotherapy. The median PFS and PFS-12 were 11 months and 39%, respectively. Outcome did not differ between the histologic cohorts. No patient achieved a radiographic response. The most common grade 3 or greater adverse events were neutropenia (11%), thrombocytopenia (3%), and diarrhea (3%). CONCLUSIONS:Imatinib plus hydroxyurea was well tolerated among recurrent/progressive LGG patients but this regimen demonstrated negligible antitumor activity.
Authors: A P Kyritsis; W K Yung; K A Jaeckle; J Bruner; M J Gleason; S E Ictech; A Flowers; V A Levin Journal: Neurosurgery Date: 1996-11 Impact factor: 4.654
Authors: S E Kaba; A P Kyritsis; K Hess; W K Yung; R Mercier; S Dakhil; K A Jaeckle; V A Levin Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: M Maxwell; S P Naber; H J Wolfe; T Galanopoulos; E T Hedley-Whyte; P M Black; H N Antoniades Journal: J Clin Invest Date: 1990-07 Impact factor: 14.808
Authors: J R Geyer; P M Zeltzer; J M Boyett; L B Rorke; P Stanley; A L Albright; J H Wisoff; J M Milstein; J C Allen; J L Finlay Journal: J Clin Oncol Date: 1994-08 Impact factor: 44.544
Authors: M Hermanson; K Funa; M Hartman; L Claesson-Welsh; C H Heldin; B Westermark; M Nistér Journal: Cancer Res Date: 1992-06-01 Impact factor: 12.701
Authors: Michael Wahl; Susan M Chang; Joanna J Phillips; Annette M Molinaro; Joseph F Costello; Tali Mazor; Sanda Alexandrescu; Janine M Lupo; Sarah J Nelson; Mitchel Berger; Michael Prados; Jennie W Taylor; Nicholas Butowski; Jennifer L Clarke; Daphne Haas-Kogan Journal: Cancer Date: 2017-07-31 Impact factor: 6.860
Authors: Kurt A Jaeckle; S K Anderson; Erin L Twohy; Jesse G Dixon; Caterina Giannini; Robert Jenkins; Merrill J Egorin; Jann N Sarkaria; Paul D Brown; P J Flynn; John Schwerkoske; Jan C Buckner; Evanthia Galanis Journal: J Neurooncol Date: 2019-05-22 Impact factor: 4.130
Authors: Astrid Jeibmann; Kathrin Halama; Hanna Theresa Witte; Su Na Kim; Kristin Eikmeier; Björn Koos; Christian Klämbt; Werner Paulus Journal: J Neurooncol Date: 2015-07-30 Impact factor: 4.130
Authors: Brian V Nahed; Navid Redjal; Daniel J Brat; Andrew S Chi; Kevin Oh; Tracy T Batchelor; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson Journal: J Neurooncol Date: 2015-11-03 Impact factor: 4.130